×
Manchester researchers use AI to simulate cancer patient trials
Written by
Published on
Join our daily newsletter for breaking news, product launches and deals, research breakdowns, and other industry-leading AI coverage
Join Now

AI-powered virtual cancer trials: Researchers at the University of Manchester and The Christie cancer hospital have received a £5.9 million grant from Cancer Research UK to develop AI-simulated clinical trials for cancer treatments.

  • The project aims to test the effectiveness of radiotherapy treatments on virtual patients created using real-life data, potentially accelerating research and reducing costs compared to traditional clinical studies.
  • Professor Rob Bristow, the lead researcher, emphasizes that these simulated trials will make cancer research “faster, safe and less expensive” than large-scale clinical studies involving real patients.
  • The AI-driven approach allows for faster testing of ideas and treatments compared to conventional trials, potentially leading to more rapid advancements in cancer care.

Historical context and radiotherapy background: The Christie hospital and Cancer Research UK have a long-standing history of pioneering radiotherapy research, dating back to the 1920s.

  • Radiotherapy, which uses X-ray radiation to kill cancer cells by damaging their DNA, remains a crucial treatment method in oncology.
  • The north-west of England sees an estimated 44,000 new cancer diagnoses each year, highlighting the importance of continued research and innovation in cancer treatment.

Project focus and funding details: The £5.9 million grant will support the research project for five years, with a specific emphasis on personalized cancer treatment and comparative studies.

  • Researchers will investigate patient-specific genetics and tumors to tailor treatments more effectively.
  • The team will compare a new form of proton beam therapy with standard radiotherapy for lung cancer patients, potentially identifying more effective treatment options.
  • The AI-powered virtual trials will allow for rapid testing of various treatments and devices, accelerating the research process.

Real-world impact and patient perspective: The potential benefits of this research extend beyond the laboratory, offering hope to cancer patients and survivors.

  • Martin Storey, a lung cancer survivor who participated in a clinical trial involving radiotherapy, expressed enthusiasm for the AI-driven approach to advancing cancer treatment.
  • Storey’s personal experience underscores the life-changing impact of cancer research and clinical trials, as he credits his survival to participating in a trial.
  • The use of AI and virtual trials could potentially increase the number of patients who benefit from cutting-edge treatments by streamlining the research process.

Future implications and potential outcomes: The integration of AI into cancer research represents a significant step forward in the field of oncology.

  • If successful, this approach could lead to more efficient and cost-effective clinical trials, potentially accelerating the development of new cancer treatments.
  • The focus on personalized medicine, considering patient-specific genetics and tumor characteristics, aligns with the broader trend towards precision oncology.
  • As AI technology continues to advance, it may play an increasingly important role in various aspects of cancer research and treatment, potentially improving outcomes for patients worldwide.
Radiotherapy: Manchester scientists use AI to simulate cancer patient trials

Recent News

OnePlus 12 receives Android 15 update without AI features

OnePlus leads non-Google manufacturers in Android 15 rollout, with AI features to follow later.

AI polling firm admits flaws in US election predictions

AI-powered polling startup's prediction miss sparks debate on technology's role in election forecasting.

Stanford HAI: AI accountability improves with third-party evaluations

Independent evaluations of AI systems face challenges but are crucial for responsible development and deployment.